H.C. Wainwright Raises its Price Target on CG Oncology, Inc. (CGON) to $80 and Maintains a Buy Rating

On February 27, 2026, H.C. Wainwright raised the firm's terms people connected CG Oncology, Inc. (NASDAQ:CGON) to $80 from $75 and maintained a Buy standing connected the shares. The expert said the institution is advancing toward a biologics exertion submission for cretostimogene successful high-risk non-muscle invasive bladder cancer, supported by beardown durability and information data, portion besides expanding into earlier attraction settings. The steadfast added that the Phase 3 PIVOT-006 proceedings successful intermediate-risk NMIBC represents a cardinal 2026 catalyst that could importantly broaden the company’s objective and commercialized opportunity.

On February 27, 2026, CG Oncology, Inc. (NASDAQ:CGON) reported FY25 EPS of ($2.08), compared with statement estimates of (58c). The institution reported gross of $4.04M, supra the $515,180 statement estimate. Chairman and CEO Arthur Kuan said the institution expects to study topline information from PIVOT-006 successful the coming months, describing the survey arsenic “the archetypal randomized registrational proceedings to measure an investigational therapy successful intermediate-risk NMIBC.” Kuan added that the institution believes it has the accidental to found a caller modular successful intermediate-risk NMIBC and highlighted cretostimogene’s “unique best-in-disease profile.” He besides noted that results from CORE-008 Cohort CX successful high-risk BCG-exposed patients evaluating cretostimogene successful operation with gemcitabine are expected successful the coming quarter.

CG Oncology, Inc. (NASDAQ:CGON) is simply a late-stage objective biopharmaceutical institution that develops and commercializes bladder-sparing therapeutics for patients with bladder cancer.

While we admit the imaginable of CGON arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 12 Best Tech Stocks that Beat Earnings Estimates and 40 Most Popular Stocks Among Hedge Funds Heading Into 2026

Disclosure: None. Follow Insider Monkey connected Google News.